← Eichor
Condition: Hemorrhagic Risk Conditions Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Hemorrhagic Risk Conditions

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
Phase 2 · 1 location(s) · University of Rochester · NCT05597345MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myel
Phase N/A · 2 location(s) · MPN Research Foundation · NCT07362225Risk Stratification and MRD-driven Maintenance for MM After ASCT
NA · 4 location(s) · Peking University People's Hospital · NCT06697483Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
Phase N/A · 1 location(s) · Institut Pasteur du Cambodge · NCT07358910Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT03314974A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Phase 3 · 2 location(s) · Regeneron Pharmaceuticals · NCT07393282Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523555REGistry of Long-term AnTithrombotic TherApy-2
Phase N/A · 1 location(s) · National Medical Research Center for Cardiology, Ministry of · NCT04347187The Neonatal Hemorrhagic Risk Assessment in Thrombocytopenia
Phase N/A · 8 location(s) · Karolinska Institutet · NCT04598750Ex Vivo Reproduction of Minimally Invasive Surgery With Hematoma Lysis Using Modified Tissue Plasminogen Activator for I
Phase N/A · 1 location(s) · University Hospital, Lille · NCT07411079The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma
Phase 1/Phase 2 · 1 location(s) · Oslo University Hospital · NCT05841550Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Ste
EARLY_Phase 1 · 1 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT06398457Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
Phase 2 · 3 location(s) · Irene Ghobrial, MD · NCT05469893REGistry of Long-term AnTithrombotic TherApy-1
Phase N/A · 1 location(s) · National Medical Research Center for Cardiology, Ministry of · NCT04347200AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positiv
Phase 3 · 42 location(s) · University Hospital, Brest · NCT05198960Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura
Phase 1 · 1 location(s) · New York Medical College · NCT04323748Metabolic and Infectious Diseases in La Réunion (the REUNION Population-based Study)
Phase N/A · 1 location(s) · Institut National de la Santé Et de la Recherche Médicale, F · NCT05400824
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.